Inhibition of the RAAS using anti-Ang II vaccines, administration of Ang (1–7), and ACE2 overexpression recently emerged as a promising new tool for myocardial fibrosis management in animal models and even in small clinical trials. The gene discussed is AGT; the disease is Myocardial fibrosis.